<DOC>
	<DOCNO>NCT01918761</DOCNO>
	<brief_summary>To identify dose dacomitinib combination pemetrexed safe tolerate determined incidence DLTs ( dose limit toxicity ) .</brief_summary>
	<brief_title>Dacomitinib + Pemetrexed Patients With Advanced Non-squamous Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This open label phase Ib trial aim determine safety , tolerability , pharmacokinetic profile , identify dose dacomitinib combination pemetrexed . Three site Austria participate study . Six nine patient initially enrol receive target dose 45 mg qd dacomitinib ( start day 2 first cycle ) combination pemetrexed ( 500 mg/m² 10 min infusion , every 3 week ) . One cycle define 21 day . The first 3 subject enrol rate ≤ 1 subject per week . If target dose regimen safe base incidence DLT another 3 subject enrol . If dose 45 mg qd safe alternate lower dos explore ( dose level -1 , dose level -2 ) identify MTD dacomitinib combination pemetrexed . Six nine patient per dose level enrol .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Written inform consent Histologically cytologically confirm stage IV nonsquamous NSCLC Patients candidate receive pemetrexed monotherapy If pemetrexed administer first line therapy must treatment free interval least one cycle ( 21 day ) Measurable disease RECIST criterion version 1.1 . ≥18 year age ECOG PFS 02 LVEF ≥ 50 % either echocardiogram MUGA Adequate organ function , include : Adequate bone marrow reserve : absolute neutrophil count ( ANC ) ≥ 1500 cells/mm3 , platelet ≥100.000 cells/mm3 Creatinine clearance ≥ 45 mL/min Total bilirubin &lt; 1.5 x ULN AST ( SGOT ) &lt; 3 x ULN ( &lt; 5.0 x ULN hepatic metastasis ) ALT ( SGPT ) &lt; 3 x ULN ( &lt; 5.0 x ULN hepatic metastasis ) Female patient partner must postmenopausal ( defined 12 month amenorrhea follow last menses ) , surgically sterile must agree use effective contraception receive trial treatment least 3 month thereafter ( definition effective contraception base judgment investigator ) . Male patient partner must surgically sterile must agree use barrier method contraception receive trial treatment least 3 month thereafter . ( In case definition effective contraception base judgment investigator ) . Able comply require protocol procedure able receive oral medication Any evidence mixed histology include element small cell carcinoid lung cancer Predominantly squamous cell histology Patients symptomatic brain metastasis Chemotherapy , radiotherapy , biological investigational agent within two week baseline disease assessment Patients uncontrolled significant cardiovascular disease , include : Myocardial infarction within 12 month Uncontrolled angina within 6 month Congestive heart failure within 6 month Diagnosed suspected congenital long QT syndrome Any history clinically significant ventricular arrhythmia ; Prolonged QTc interval pre entry electrocardiogram . QTc must less CTC Grade 2 ( ≤480 msec ) use appropriate correction formula manual read investigator require . The ECG may repeat evaluation eligibility management correctable cause observe QTc prolongation currently pacemaker ) Heart rate &lt; 50/minute baseline electrocardiogram Uncontrolled hypertension Prior malignancy : Patients eligible evidence malignancy ( non melanoma skin cancer situ cervical cancer , localize presume cured prostate cancer PSA &lt; ULN ) within last 3 year . Pregnant lactating female . Serum pregnancy test assess within 7 day prior study treatment start.Known hypersensitivity pemetrexed and/or dacomitinib Patients exposure investigational drug therapy Previous therapy oral TKI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Dacomitinib</keyword>
</DOC>